Posted by Michael Wonder on 26 Oct 2021
Cystic fibrosis medicine added to PHARMAC's options for investment list
27 October 2021 - PHARMAC has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has been added to the priority list of medicines it would like to fund.
In July this year, pharmaceutical company Vertex applied to PHARMAC for its triple combination modulator therapy to be funded for people aged over 6 with cystic fibrosis.
